Chorionic gonadotropin subunit beta (beta-hCG) (beta-hCG)

Chorionic gonadotropin subunit beta (beta-hCG) is a glycoprotein hormone subunit that is physiologically produced by the placenta to maintain the corpus luteum during pregnancy (UniProt: P01233). In the context of oncology, beta-hCG is frequently expressed ectopically by a wide range of non-trophoblastic malignancies, including bladder, lung, and colorectal cancers, where it functions as an autocrine and paracrine growth factor (PMID: 24651013). Within the tumor microenvironment, it promotes cell proliferation, inhibits apoptosis, and facilitates immune evasion, often correlating with poor clinical prognosis and increased metastatic potential (PMID: 25633835). Because its expression is highly restricted in healthy non-pregnant adults, it is considered a promising tumor-associated antigen for targeted immunotherapy. Current therapeutic strategies include therapeutic vaccines, monoclonal antibodies, and CAR-T cell therapies designed to recognize the beta subunit or its unique C-terminal peptide (PMID: 30154034). A significant challenge in targeting this molecule is its structural homology with Luteinizing Hormone (LH), which requires high specificity to avoid off-target endocrine toxicity (PMID: 17003680).

Other names

CGBCGB3hCGBHuman chorionic gonadotropin beta subunitChoriogonadotropin subunit beta

The mechanism of action for drugs targeting beta-hCG involves the induction of immune-mediated cell death through antibody-dependent cellular cytotoxicity (ADCC) or T-cell activation, as well as the neutralization of hCG-mediated signaling pathways that promote tumor survival, angiogenesis, and immune suppression (PMID: 24651013, PMID: 17003680).